Please login to the form below

Not currently logged in
Email:
Password:

Syntaxin

This page shows the latest Syntaxin news and features for those working in and with pharma, biotech and healthcare.

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase. French pharma firm also agrees research deal with Harvard. ... The drug, like Syntaxin's other investigational compounds, is a targeted secretion inhibitor (TSI).

Latest news

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics